Parkinson's Tozadenant Trial Discontinued Posted by Rachel Dolhun, MD, November 15, 2017 March, 12, 2018 UPDATE: 11/20/2017 Acorda Therapeutics, Inc. today announced discontinuation of its tozadenant clinical development program based on information related to serious adverse events.
On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial. They concluded that they could not be confident that weekly ...
Study Title: Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patient's Using Levodopa (TOZ-PD) ClinicalTrails.gove Identified ...
Many patients with Parkinson's disease have motor fluctuations despite treatment with available drugs. Tozadenant (SYN115) is an oral, selective adenosine A2A receptor antagonist that improves motor function in animal models of Parkinson's disease.
The trial is comparing two of doses of Tozadenant (60 mg and 120 mg) and comparing it to placebo, and it is assessing improvements in motor function and daily living in people with Parkinson’s. The results of the trial are expected in the first quarter of 2018.
Tozadenant (SYN115) is an inhibitor of the adenosine 2a (A2a) receptor that is being developed for the treatment of Parkinson's Disease. For more information go to SYN115 Compared with the use of a placebo, daily off-time was reduced by more than an hour when taking either 120mg or 180mg tozadenant.
Read about the current development status of two Acorda therapies to treat Parkinson's disease, CVT-301 and tozadenant.
Acorda Therapeutics, Inc. ACOR recently announced that it is scrapping development of one of its lead Parkinson's disease ("PD") candidates, tozadenant. The decision ...
(Reuters) - Acorda Therapeutics Inc said on Monday it would stop developing its Parkinson’s disease drug, tozadenant, less than a week after the company reported deaths in key studies testing the treatment.